Division of Cyberonics Inc./Sorin Group SPA
Latest From CarboMedics Inc.
Sorin's history of important technology breakthroughs has long been one of the best kept secrets in the cardiac rhythm management market. The company is now restructuring to focus on CRM, particularly in the US, and challenge the major players on their home turf.
Recent safety issues with drug-eluting stents may have opened the door ever so slightly for cardiac surgeons and coronary artery bypass graft (CABG) surgery to stage a small but noticeable comeback in the treatment of coronary artery disease.
The contribution that Europeans, particularly European physicians and surgeons, have made to the cardiology and cardiovascular industries has been enormous. Why then have Europeans lagged far behind their US counterparts in one important area--company creation? If there is a candidate to play in the cardiovascular device industry's elite ranks, it's Sorin Group, a company with a diverse holding in a wide range of cardiology and cardiovascular device segments.
In the early 1990s, St. Jude Medical was the market leader in its sole product area: mechanical heart valves, which placed it among the most profitable of device companies. Demographics, however, limited heart valves' future growth opportunities and St. Jude needed to diversify, moving into cardiac rhythm management (CRM), cardiology catheters, and vascular access devices, while also expanding in cardiac surgery. The diversification process went anything but smoothly, the company missed its numbers, and investors were quick to punish St. Jude for its integration missteps. In the past year, however, the company has become one of Wall Street's few device darlings, ranking number one in 2000 for returns among device stocks. The company's growth is largely the result of sticking to a strategy that has St. Jude well-positioned in CRM's traditional markets, while also poised to pursue huge new opportunities in atrial fibrillation and, to a lesser degree, congestive heart failure. And St. Jude has not forgotten its base: cardiac surgery, where the company has introduced new sutureless anastomotic technology for minimally invasive coronary bypass surgery.
- Medical Devices
- Therapeutic Areas
- Sulzer Carbomedics Inc.
- North America
- Parent & Subsidiaries
- Cyberonics Inc.
- Senior Management
Terry L Marlatt, Pres., Cardiovascular Div.
Pamela Westbrook, VP, Fin. & Controlling
Rusty E Phillips, VP, R&D
Rex Nagao, VP, Mktg.
Richard H Sorenson, VP, Bus. Dev.
Chuck Griffin, Pres.
- Contact Info
Phone: (512) 435-3200
1300 E. Anderson Ln.
Austin, TX 78752